JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Unger, E. L.
Right arrow Articles by Andrews, A. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Unger, E. L.
Right arrow Articles by Andrews, A. M.

Vol. 303, Issue 2, 527-533, November 2002

2'-NH2-MPTP [1-Methyl-4-(2'-aminophenyl)-1,2,3,6-tetrahydropyridine] Depletes Serotonin and Norepinephrine in Rats: A Comparison with 2'-CH3-MPTP [1-Methyl-4-(2'-methylphenyl)-1,2,3,6-tetrahydropyridine]

Erica L. Unger, Pascale Mazzola-Pomietto, Dennis L. Murphy and Anne M. Andrews

Department of Chemistry, Pennsylvania State University, University Park, Pennsylvania (E.L.U., A.M.A.); Institut National de la Santé et de la Recherche Médicale, Marseilles, France (P.M.-P.); and Laboratory of Clinical Science, National Institute of Mental Health, Bethesda, Maryland (D.L.M.)

The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) analog, 1-methyl-4-(2'-aminophenyl)-1,2,3,6-tetrahydropyridine (2'-NH2-MPTP), depletes brain serotonin and norepinephrine in mice without affecting striatal dopamine. The present study was conducted to determine whether 2'-NH2-MPTP would be similarly neurotoxic to rats. Four injections of 20 mg/kg 2'-NH2-MPTP caused 80 to 90% depletions in serotonin and norepinephrine in frontal cortex and hippocampus in rats 1 week post-treatment. A lower dose of 2'-NH2-MPTP (4 × 15 mg/kg) also produced large decrements in serotonin and norepinephrine levels and in serotonin transporter density measured 3 weeks after neurotoxin administration. Furthermore, this lower dose of 2'-NH2-MPTP altered functional serotonin neurotransmission as evidenced by a 2-fold potentiation of 1-(3-chlorophenyl)-piperazine·2HCl-induced hyperthermia, an index of serotonergic denervation supersensitivity. At both doses, 2'-NH2-MPTP was without effect on striatal dopamine. For comparison, additional rats were treated with a second 2'-substituted analog of MPTP, 1-methyl-4-(2'-methylphenyl)-1,2,3,6-tetrahydropyridine (2'-CH3-MPTP), at 2 × 20 mg/kg. This dosing regimen causes substantial striatal dopamine depletion in mice. 2'-CH3-MPTP had no effect on brain levels of serotonin, norepinephrine, or dopamine in rats. Together, these results demonstrate that rats are sensitive to the toxic effects of 2'-NH2-MPTP but not to 2'-CH3-MPTP at doses known to cause neurotoxicity in mice. Moreover, this study clearly shows that 2'-NH2-MPTP can be utilized in rats as a tool to study the serotonergic and noradrenergic neurotransmitter systems.


0022-3565/02/3032-0527$07.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2002 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Mol. Pharmacol.Home page
A. L. Numis, E. L. Unger, D. L. Sheridan, A. C. Chisnell, and A. M. Andrews
The Role of Membrane and Vesicular Monoamine Transporters in the Neurotoxic and Hypothermic Effects of 1-Methyl-4-(2'-aminophenyl)-1,2,3,6-tetrahydropyridine (2'-NH2-MPTP)
Mol. Pharmacol., September 1, 2004; 66(3): 718 - 727.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
B. A. Luellen, D. B. Miller, A. C. Chisnell, D. L. Murphy, J. P. O'Callaghan, and A. M. Andrews
Neuronal and Astroglial Responses to the Serotonin and Norepinephrine Neurotoxin: 1-Methyl-4-(2'-aminophenyl)-1,2,3,6-tetrahydropyridine
J. Pharmacol. Exp. Ther., December 1, 2003; 307(3): 923 - 931.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2002 by the American Society for Pharmacology and Experimental Therapeutics.